Site Search
Professionals 133 results
Capabilities 49 results
Practice Area
Employee Benefits & Executive Compensation
With attorneys based in Chicago, New York and Washington, D.C., Winston’s Employee Benefits & Executive Compensation (EBEC) team represents a broad range of plan sponsors and offers clients not just deal support but the full suite of employee benefit services. These include public company reporting and executive compensation, employee benefits in mergers and acquisitions, qualified retirement plans and Title I investment advice, health and welfare benefit plans, employee stock ownership plans (ESOPs), and international human resources matters. And driven by a volatile labor market, we are partnering with clients to innovate plan structure and design, including cutting-edge services such as private exchange medical benefits, employee benefits in captive insurance, and fiduciary governance best practices. With decades of experience, our EBEC team maintains strong brand recognition, with clients describing our attorneys as “superb,” “very client-friendly,” “extremely responsive and able to bring forth the right resources,” and “having an “incredible breadth of knowledge.”
Practice Area
Environmental Litigation & Enforcement
With today’s rapidly evolving rules of engagement, paired with the often contentious nature of environmental disputes, clients rely on Winston for our practical experience and substantive knowledge of the broad-ranging issues involved in environmental litigation, enforcement, and investigations.
Region
Winston’s deep experience representing companies and investors across Latin America and the Caribbean has made the firm a “go-to” resource for the strategic development of our clients’ businesses and the vigorous protection of their interests in the region. With broad command of a diverse range of issues within the region’s key industry sectors, we advise Fortune 500 companies, government and quasi-governmental entities, financial institutions, private equity and other investors, domestic and international oil and gas exploration and production companies, refiners and shippers, and a range of commercial and infrastructure developers.
Experience 19 results
Experience
|January 22, 2026
Advised SQM on US$600M offering of subordinated capital notes due 2056 (Hybrid Bond Offering)
Winston & Strawn LLP advised longstanding client Sociedad Química y Minera de Chile S.A. (“SQM”) (NYSE: SQM) on its US$600 million offering of subordinated capital notes. The notes were offered in the United States pursuant to Rule 144A and outside the United States pursuant to Regulation S.The subordinated capital notes are due in 2056 and constitute SQM’s first international hybrid bond issuance, structured to be consistent with SQM’s recent UF 10 million (approximately US$ 430 million) Series S hybrid-subordinated bond issuance in the Chilean securities market. The notes bear an initial annual interest rate of 5.625% and are subject to reset on April 22, 2031 (the “First Reset Date”), and on every fifth anniversary thereafter, based on a spread over the 5-year U.S. Treasury bond rate, with interest rate step-ups on the fifth and twentieth anniversaries of the First Reset Date. The transaction closed on January 22, 2026.BofA Securities, Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Santander US Capital Markets LLC, and Scotia Capital (USA) Inc. acted as initial purchasers of the notes.Link Capital Partners was financial advisor to SQM.SQM is a global company with a leading position in the lithium, iodine, and potassium nitrate markets. It develops and produces a diverse range of products for industries essential to human progress, including health, nutrition, renewable energy, and technology, driven by innovation and technological development.The Winston & Strawn team advising on the transaction included corporate partner Sey-Hyo Lee (New York) and foreign legal advisor Bruno M. Fiorino (New York). Partner Katherine Erbeznik (New York) advised on tax matters.
Experience
|July 17, 2025
D. Boral Capital Closes US$15M Robot Consulting IPO
Winston & Strawn LLP represented D. Boral Capital LLC and Craft Capital Management LLC in connection with the US$15M initial public offering of American Depositary Shares (ADSs) of Robot Consulting Co., Ltd. The offering consisted of 3,750,000 ADSs priced at $4.00 per ADS, and the company’s ADSs began trading on the Nasdaq Capital Market under the ticker symbol “LAWR” on July 17, 2025.
Experience
|March 31, 2025
Winston & Strawn assists Santa Fe Operating, LLC, a subsidiary of HRM Resources IV, LLC, a Kayne Anderson Capital Advisors sponsor-backed borrower, in reserve-based $300,000,000 lending facility with BOKF, NA, the proceeds of which were used to acquire producing oil and gas properties.
Insights & News 1,179 results
Sponsorship
|March 22, 2026
Winston & Strawn Sponsors 38th Annual Roth Conference
Winston & Strawn is proud to sponsor the 38th Annual Roth Conference. This year, the program will feature one-on-one and small group meetings, analyst-selected fireside chats, industry keynotes, and panel discussions.
Recognitions
|March 10, 2026
|1 Min Read
Winston Recognized During Global Banking & Markets Awards: Latin America & Caribbean 2026
Winston & Strawn was recognized as a legal advisor on the Chile Electricity Lux MPC senior secured financing, which received the Global Banking & Markets Power Finance Deal of the Year Award. The honor was announced at an awards ceremony held in Miami on February 26, 2026. This marks the third award earned by this landmark transaction, which represents the largest mobilization of private resources ever undertaken by IDB Invest.
In the Media
|March 10, 2026
|2 Min Read
Winston & Strawn’s New Miami Office Draws Headlines
Winston’s move to its new Miami office has drawn attention from local and industry media, including Daily Business Review, South Florida Business Journal, and more. The coverage highlights how the firm’s move to the 17thand 18thfloors at 200 S. Biscayne Boulevard reflects the firm’s ongoing commitment to investing in its clients, its people, and the communities in which it operates.
Other Results 66 results
Site Content
A subset of biologics, a biosimilar is a biologic that is highly similar to an FDA-approved product, referred to as the reference product. Biosimilars have no clinically meaningful differences compared to a reference product in terms of safety, purity, and potency as demonstrated through human pharmacokinetic and pharmacodynamics studies. Because of their complexity, biosimilars are unlikely to be identical replicates of their comparable reference products.
Site Content
In the product liability context, epidemiology refers to the study of the incidence, distribution, and etiology of disease or harm in human populations. Epidemiological studies include a variety of different study designs, such as prospective and retrospective cohort studies, case-control studies, randomized controlled trials, and meta-analysis. Epidemiology is a critical, and sometimes mandatory, element for establishing general causation.